Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models

09-Feb-2010 - Switzerland
Addex Pharmaceuticals announced that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. In the first model, ADX71943 reversed complete Freund adjuvant (CFA)-induced reductions in withdrawal thresholds in a dose-related manner, with a minimum statistically significant effective oral dose of 10 mg/kg. In a second model (Formalin test), ADX71943 showed anti-nociceptive effect after oral administration of 3 to 10 mg/kg. In a third model, an increased visceral pain threshold was seen using ADX71943 with a minimum statistically significant effective dose between 3 and 10 mg/kg. ADX71943 is an orally available positive allosteric modulator (PAM) of the GABA(B) receptor that has potential for treatment of osteoarthritis pain and chronic nociceptive pain as well as other indications. ADX71943 has a good developability profile and is expected to enter clinical testing in the fourth quarter 2010.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances